


Typhoid conjugate vaccine (TCV) provides strong protection in Africa *and* Asia

Location	Nepal		Malawi		Bangladesh	
Number of participants	20,019		27,882		61,567	
Ages of participants	9 months to <16 years		9 months to <12 years		9 months to <16 years	
Study design	Randomized 1:1 <i>TCV or meningococcal A (MenA) vaccine</i>		Randomized 1:1 <i>TCV or MenA vaccine</i>		Cluster* randomized 1:1 <i>TCV or Japanese encephalitis (JE) vaccine</i>	
Length of follow-up	24 months		48-54 months		18 months	
Blood-culture confirmed typhoid cases	TCV: 13	Meningococcal A: 62	TCV: 24	MenA: 110	TCV: 29	JE: 192
Vaccine efficacy	TCV prevents 78-85% of typhoid cases in children in Africa and Asia. 					
Vaccine safety	Meets safety standards ✓		Meets safety standards ✓		Meets safety standards ✓	

*In cluster randomized trials, groups of participants (known as clusters) are randomized as opposed to individual participants being randomized.